SynthesisAbdominal radiology (New York)2026
Imaging surveillance outcomes of hepatocellular adenomas: systematic review and meta-analysis.
Synthesis in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesHepatocellular adenomas (HCA) are typically resected if > 5 cm after 6 months due to historical risks of bleeding and malignant transformation. Outcomes of contemporary patients managed with surveillance are not well defined. We performed a systematic review and meta-analysis of patients with HCAs monitored for ≥ 6 months to assess rates of size stability, bleeding, and malignant transformation.
methodsPubMed, Web of Science, and Embase databases were searched up to August 2025 for all articles reporting HCA and follow-up. Risk of bias was assessed with modified Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool. Pooled proportions of outcomes were assessed with linear mixed model and logistic regression. Heterogeneity was assessed with the I
resultsOf 679 articles screened, 7 retrospective studies (2019-2023) with 699 patients across Europe and United States were included. Five were multicenter. Median follow-up ranged from 2 to 5.8 years. For size stability, four studies used Response Evaluation Criteria in Solid Tumors (RECIST); others used a 1 cm size threshold, regression to < 5 cm, or unspecified criteria. Six studies showed moderate to serious risk of bias. Pooled proportion of HCAs that were stable or regressed was 88.5%. Pooled incidences of symptomatic bleeding and malignant transformation were 0.5% and 0.8%, respectively.
conclusionIn a contemporary series, the majority of untreated HCAs were stable or regressed during surveillance, with extremely low incidences (< 1%) of bleeding and malignant transformation. Extending surveillance intervals may safely offer patients more time to address modifiable risk factors.
Indexed as
Identifiers
41364225What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.